Antibe Therapeutics, Inc. (Otc) (TSE:ATE) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Antibe Therapeutics Inc. has undergone significant changes, with the appointment of FTI Consulting Canada Inc. as receiver following the termination of its CCAA proceedings, and the resignation of five board members. Additionally, the company’s common shares are set to be delisted from the TSX on May 24, 2024.
For further insights into TSE:ATE stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue